Association of phosphodiesterase 4D gene with ischemic stroke in a Pakistani population

Stroke

Volumn 36, Issue 10, 2005, Pages 2275-2277

  Saleheen, Danish ^a,d   Bukhari, Shabbar ^a   Haider, Shajjia Razi ^a   Nazir, Aisha ^a   Khanum, Shaheen ^a   Shafqat, Saad ^b   Anis, M Kashif ^b,c   Frossard, Philippe ^a  

^a AGA KHAN UNIVERSITY   (Pakistan)

^b AGA KHAN UNIVERSITY HOSPITAL   (Pakistan)

^c CIVIL HOSPITAL   (Pakistan)

^d AGA KHAN UNIVERSITY MEDICAL COLLEGE   (Pakistan)

Author keywords

Genetics; Risk factors; Stroke, ischemic

Indexed keywords

PHOSPHODIESTERASE 4D; PHOSPHODIESTERASE IV; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; FEMALE; GENE LINKAGE DISEQUILIBRIUM; GENE LOCUS; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PAKISTAN; PATHOGENESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; AGED; ALLELES; BRAIN; BRAIN ISCHEMIA; CASE-CONTROL STUDIES; CEREBROVASCULAR ACCIDENT; DNA PRIMERS; FEMALE; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; GENETICS, POPULATION; GENOTYPE; HAPLOTYPES; HOMOZYGOTE; HUMANS; LINKAGE DISEQUILIBRIUM; MALE; MIDDLE AGED; MODELS, STATISTICAL; MULTIVARIATE ANALYSIS; ODDS RATIO; PAKISTAN; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; RISK FACTORS; VARIATION (GENETICS);

EID: 26444498537     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.0000182242.59466.ee     Document Type: Article

References (10)

1. American Heart Association. Heart Disease and Stroke Statistics-2003 Update. Dallas, Tex: American Heart Association; 2002.
2. World Health Organization (WHO). The Atlas of Heart Disease and Stroke. http://www.who.int/cardiovascular_diseases/resources/atlas/en/ (accessed December 18, 2004).
3. Bulatao RA, Stephens PW. Global estimates and projections of mortality by cause. Washington, DC: Population, Health and Nutrition Department; World Bank, preworking paper 1992; 1007.
4. Alberts MJ. Genetics of cerebrovascular disease. Stroke. 2004;35:342-344.
5. Gretarsdottir S, Sveinbjornsdottir S, Jonsson HH, Jakobsson F, Einarsdottir E, Agnarsson U, Shkolny D, Einarsson G, Gudjonsdottir HM, Valdimarsson EM, Einarsson OB Thorgeirsson G, Hadzic R, Jonsdottir S, Reynisdottir ST, Bjarnadottir SM, Gudmundsdottir T, Gudlaugsdottir GJ, Gill R, Lindpaintner K, Sainz J, Hannesson HH, Sigurdsson GT, Frigge ML, Kong A, Gudnason V, Stefansson K, Gulcher JR. Localization of a susceptibility gene for common forms of stroke to 5q12. Am J Hum Genet. 2002;70:593-603.
6. Gretarsdottir S, Thorleifsson G, Reynisdottir ST, Manolescu A, Jonsdottir S, Jonsdottir T, Gudmundsdottir T, Bjarnadottir SM, Einarsson OB, Gudjonsdottir HM. The gene encoding phosphodiesterase 4D confers risk of ischemic stroke. Nat Genet. 2003;35:131-138.
7. Gauderman WJ. Sample size requirements for association studies of gene-gene interaction. Am J Epidemiol. 2002;155:478-484.
8. Lohmussaar E, Gschwendtner A, Mueller JC, Org T, Wichmann E, Hamann G, Meitinger T, Dichgans M. ALOX5AP gene and the PDE4D gene in a central European population of stroke patients. Stroke. 2005;36:731-736.
9. Birk S, Edvinsson L, Olesen J, Krause C. Analysis of the effects of phosphodiesterase type 3 and 4 inhibitors in cerebral arteries. Eur J Pharmacol. 2004;489:93-100.
10. Stoclet JC, Keravis T, Komas N, Lugnier C. Cyclic nucleotide phophodiesterases as therapeutic targets in cardiovascular diseases. Expert Opin Investig Drugs. 1995;4:1081C-1100C.